Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
Abstract Background Schizophrenia is a serious mental health condition characterised by distortions in thought processes, perception, mood, sense of self, and behaviour. Lurasidone, a second-generation atypical antipsychotic, represents an additional treatment option alongside existing antipsychotic...
Saved in:
Main Authors: | Amy Dymond (Author), Daniela Afonso (Author), Will Green (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lurasidone for the treatment of schizophrenia in adult and paediatric populations
by: Teresa Guilera, et al.
Published: (2023) -
Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022) -
Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022) -
Clinical potential of lurasidone in the management of schizophrenia
by: Samalin L, et al.
Published: (2011) -
Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
by: Miura I, et al.
Published: (2023)